Search

everythinglearnresearchcommunity

for

Search:↓

The post discusses whether finasteride can maintain hair growth stimulated by minoxidil. The response indicates that finasteride cannot sustain minoxidil-grown hairs.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

Kintor changed their KX-826 pictures on Amazon after backlash over fake images. Users are skeptical about the product's effectiveness and trustworthiness, with some preferring finasteride instead.

, I’m on fin as well. This conversation discussed the user's successful results from 5 weeks of taking an oral minoxidil medication and their experience with hair shedding while using it in combination with finasteride.

The safety and effectiveness of RU-58841 as a hair loss treatment, with some users reporting side effects like chest pains, while others had positive results. The original research on RU-58841 was likely stopped due to financial issues, not safety concerns.

Hair regrowth in transfems is more effective due to hormonal changes, specifically estrogen, which keeps hair in growth phase longer. Treatments mentioned include anti-androgens, sex hormones, and DHT blockers like finasteride.

Finasteride can cause scalp itch and inflammation, possibly due to DHT changes, but these effects are often temporary and part of the shedding phase. Consistent use of finasteride may show results after 6 months, with potential hair regrowth and slowed hair loss.

A 19-year-old experiencing severe hair loss since 16 is using a treatment regimen of 5% minoxidil, 0.1% finasteride topical solution, 3% procapil hair serum, and 0.5 mg dutasteride daily. They are concerned about the effectiveness and potential shedding phase, with advice suggesting noticeable changes in 6 to 8 months.

A 20-year-old started using minoxidil, rosemary oil, Alpecin caffeine shampoos, scalp massager, derma rollers, and supplements for hair regrowth, seeing significant improvement initially. However, after 6 months, they noticed increased shedding and thinning, causing concern about whether this is normal or indicative of a problem.

The conversation is about the delay in the release of GT20029 phase 2 results by Kintor. It also mentions Minoxidil, finasteride, and RU58841 as treatments for hair loss.

Pyrilutamide phase 3 results showed little to no significant hair regrowth, but may be sufficient for maintaining current hair density. The user is unsure due to lack of recent discussions on pyrilutamide.

The user experienced significant hair recovery after 14 months using oral Propecia (finasteride) 1 mg daily and oral minoxidil, and recently added topical minoxidil and topical Propecia to their regimen. The doctor recommended this combination to maximize results, and the user reported no side effects, noticing improvements by the third month.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.

Clascoterone (Breezula) showed positive results for treating hair loss without affecting cortisol levels. Opinions vary, with some users optimistic about its potential and others critical of its effectiveness compared to existing treatments like finasteride.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

Kintor is starting a phase III trial for KX-826 combined with minoxidil for hair loss. Opinions vary on the potential success of the treatment, with some skepticism expressed.

The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Pyrilutamide Phase 2 results are expected in June 2022, with hopes for a better alternative to current treatments.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.

The progress of Phase I of HMI-115, a potential hair loss treatment, which consists of Minoxidil, finasteride, and RU58841. The estimated completion date is June.

KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.

First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

Some people see significant hair regrowth using treatments like finasteride and minoxidil, while others experience little to no improvement even with comprehensive treatment plans. Factors such as individual sensitivity to DHT may influence the effectiveness of these hair loss treatments.